CompletedNCT07508345END-GAMEUpdated Apr 2, 2026

Endothelial Dysfunction as a Predictive Marker of Acute Graft-Versus-Host Disease in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

An observational study in GVHD, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Completed at 1 site in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational

Study type: Observational
Model: Case-control
Time perspective: Prospective
Enrollment: 50
Ages: 18 Years to 70 Years
Sex: All

Study summary

Assess whether the CEC count in peripheral blood, analyzed at baseline T0, can predict the risk of acute GvHD onset.

Conditions studied

GVHD

In context

Lead sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 255 studies on the registry; 113 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 70 Years
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Adult patients with hematological diseases undergoing allogeneic hematopoietic stem cell transplantation at the Hematology Unit of the I.R.C.C.S. Policlinico San Matteo Foundation in Pavia.

Inclusion criteria

Aged between 18 and 70 years old
First allogeneic hematopoietic stem cell (HSC) transplant for hematological disease
Use of HSCs from bone marrow, peripheral blood, or cord blood
Use of HLA-identical related donors, haploidentical related donors, HLA-identical registry donors, registry donors with mismatches at major HLA loci
Signing of informed consent

Exclusion criteria

Exclusion Criteria:

Age \< 18 years or >70 years
Patients receiving allogeneic HSC transplantation for non-hematologic disease
Second or subsequent allogeneic HSC transplantation

Study design

Observational model: Case-control
Time perspective: Prospective
Enrollment: 50 participants (actual)
Patient registry: No

What researchers measure

Primary outcomes

Predict the risk of aGvHD onset.
Assess whether the CEC count in peripheral blood, analyzed at baseline T0, can predict the risk of acute GvHD onset.
Time frame: During the 18-month enrollment period, approximately 50 adult patients receiving HSCT are expected to be enrolled.

Study locations

1 site

Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Pavia 27100, Italy

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT07508345
Lead sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia
Responsible party: Luca Arcaini (MD, Fondazione IRCCS Policlinico San Matteo di Pavia) — Principal investigator
First posted: Apr 2, 2026
Start date: Jun 4, 2021
Primary completion: Jul 31, 2022
Completion: Jul 31, 2023
Last update: Apr 2, 2026

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Start the discussion